Scientists investigate why immunotherapy causes autoimmune problems in some cancer patients

NCT ID NCT04119713

Recruiting now Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to understand why some cancer patients develop autoimmune side effects when treated with immune checkpoint inhibitors. Researchers will analyze blood cells and genetics from 600 participants to identify features linked to these side effects. The goal is to improve safety and personalize cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors predict which cancer patients are at risk for autoimmune side effects from immunotherapy, leading to safer treatment plans.
What could go wrong: This is an observational study, not a treatment trial. It will not directly benefit participants and may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNITY CANCER IMMUNOTOXICITY ONCOLOGY

Contacts and locations

Locations

University of Pennsylvania - Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.